FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122138773> ?p ?o ?g. }

• W2122138773 endingPage "5244" @default.
• W2122138773 startingPage "5235" @default.
• W2122138773 abstract "Abstract Purpose: The PI3K/Akt/mTOR signaling pathway is aberrantly activated in many cancers. Combining ridaforolimus, an mTOR inhibitor, with MK-2206, an Akt inhibitor, may more completely block the PI3K pathway and inhibit tumor growth. Experimental Design: This phase I study assessed dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the combination of oral ridaforolimus plus oral MK-2206 in patients with advanced solid tumors. Efficacy was evaluated in patients with biomarker-identified estrogen receptor–positive breast cancer (low RAS gene signature and high Ki67 index) or castration-resistant prostate cancer (PTEN deficiency) with PI3K pathway addiction. Results: Thirty-five patients were enrolled: 11 patients in part A (three breast cancer) and 24 biomarker-eligible patients in part B (16 breast cancer, eight prostate cancer). One patient with breast cancer from part A was also found to be biomarker-eligible when tested after she had clinical response. The MTD was 10 mg/d ridaforolimus 5 d/wk + 90 mg/wk MK-2206; 1 of 17 patients experienced DLT (grade 3 rash) at this dose. The most common adverse events at MTD were rash (44.4%), stomatitis (38.9%), diarrhea (27.8%), and decreased appetite (27.8%). By investigator assessment, 2 of 16 (12.5%) evaluable patients with breast cancer had partial response; by central assessment, 2 of 14 (14.3%) evaluable patients had complete response. Two patients had durable stable disease (SD) for 416 and 285 days, respectively. No patients with prostate cancer responded; one patient had SD for ≥6 months. Conclusions: Combination ridaforolimus and MK-2206 showed promising activity and good tolerability in heavily pretreated patients with hormone-positive and -negative breast cancer exhibiting PI3K pathway dependence. Clin Cancer Res; 21(23); 5235–44. ©2015 AACR." @default.
• W2122138773 created "2016-06-24" @default.
• W2122138773 creator A5017229890 @default.
• W2122138773 creator A5017669406 @default.
• W2122138773 creator A5044143787 @default.
• W2122138773 creator A5053081930 @default.
• W2122138773 creator A5053880366 @default.
• W2122138773 creator A5055850984 @default.
• W2122138773 creator A5061237827 @default.
• W2122138773 creator A5083373965 @default.
• W2122138773 creator A5086593040 @default.
• W2122138773 creator A5089998052 @default.
• W2122138773 date "2015-11-30" @default.
• W2122138773 modified "2023-09-27" @default.
• W2122138773 title "A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies" @default.
• W2122138773 cites W2000570054 @default.
• W2122138773 cites W2002870649 @default.
• W2122138773 cites W2009800737 @default.
• W2122138773 cites W2015562061 @default.
• W2122138773 cites W2016511744 @default.
• W2122138773 cites W2019607817 @default.
• W2122138773 cites W2022577155 @default.
• W2122138773 cites W2022797759 @default.
• W2122138773 cites W2027114592 @default.
• W2122138773 cites W2043059572 @default.
• W2122138773 cites W2056445663 @default.
• W2122138773 cites W2063962249 @default.
• W2122138773 cites W2069374810 @default.
• W2122138773 cites W2074433596 @default.
• W2122138773 cites W2076168834 @default.
• W2122138773 cites W2080196131 @default.
• W2122138773 cites W2083378657 @default.
• W2122138773 cites W2087861588 @default.
• W2122138773 cites W2091627087 @default.
• W2122138773 cites W2096651314 @default.
• W2122138773 cites W2097881410 @default.
• W2122138773 cites W2102648794 @default.
• W2122138773 cites W2107441799 @default.
• W2122138773 cites W2111743784 @default.
• W2122138773 cites W2113458582 @default.
• W2122138773 cites W2117433522 @default.
• W2122138773 cites W2117787192 @default.
• W2122138773 cites W2120873267 @default.
• W2122138773 cites W2126506845 @default.
• W2122138773 cites W2127057139 @default.
• W2122138773 cites W2128223828 @default.
• W2122138773 cites W2131994307 @default.
• W2122138773 cites W2132097658 @default.
• W2122138773 cites W2135967493 @default.
• W2122138773 cites W2143645520 @default.
• W2122138773 cites W2143813908 @default.
• W2122138773 cites W2144894645 @default.
• W2122138773 cites W2146024986 @default.
• W2122138773 cites W2155018172 @default.
• W2122138773 cites W2157840751 @default.
• W2122138773 cites W2159750196 @default.
• W2122138773 cites W2161861008 @default.
• W2122138773 cites W2164521538 @default.
• W2122138773 cites W2164977235 @default.
• W2122138773 cites W2167188058 @default.
• W2122138773 cites W4214687291 @default.
• W2122138773 doi "https://doi.org/10.1158/1078-0432.ccr-15-0180" @default.
• W2122138773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26187616" @default.
• W2122138773 hasPublicationYear "2015" @default.
• W2122138773 type Work @default.
• W2122138773 sameAs 2122138773 @default.
• W2122138773 citedByCount "25" @default.
• W2122138773 countsByYear W21221387732016 @default.
• W2122138773 countsByYear W21221387732017 @default.
• W2122138773 countsByYear W21221387732018 @default.
• W2122138773 countsByYear W21221387732019 @default.
• W2122138773 countsByYear W21221387732020 @default.
• W2122138773 countsByYear W21221387732021 @default.
• W2122138773 crossrefType "journal-article" @default.
• W2122138773 hasAuthorship W2122138773A5017229890 @default.
• W2122138773 hasAuthorship W2122138773A5017669406 @default.
• W2122138773 hasAuthorship W2122138773A5044143787 @default.
• W2122138773 hasAuthorship W2122138773A5053081930 @default.
• W2122138773 hasAuthorship W2122138773A5053880366 @default.
• W2122138773 hasAuthorship W2122138773A5055850984 @default.
• W2122138773 hasAuthorship W2122138773A5061237827 @default.
• W2122138773 hasAuthorship W2122138773A5083373965 @default.
• W2122138773 hasAuthorship W2122138773A5086593040 @default.
• W2122138773 hasAuthorship W2122138773A5089998052 @default.
• W2122138773 hasBestOaLocation W21221387731 @default.
• W2122138773 hasConcept C121608353 @default.
• W2122138773 hasConcept C126322002 @default.
• W2122138773 hasConcept C143998085 @default.
• W2122138773 hasConcept C185592680 @default.
• W2122138773 hasConcept C197934379 @default.
• W2122138773 hasConcept C2778570526 @default.
• W2122138773 hasConcept C2780192828 @default.
• W2122138773 hasConcept C2781197716 @default.
• W2122138773 hasConcept C530470458 @default.
• W2122138773 hasConcept C55493867 @default.
• W2122138773 hasConcept C62478195 @default.
• W2122138773 hasConcept C71924100 @default.
• W2122138773 hasConcept C86554907 @default.

• next